Retham Technologies, Inc. has announced the launch of its next-generation functional Retham Cryoplatelets™, a novel solution designed to overcome longstanding challenges in platelet-based research and has named Prolytix, a leader in coagulation and hematology services and products, to be the distributor.
Retham Cryoplatelets were developed to address the limitations of fresh donor platelets for laboratory use by providing a consistent, stable, readily available source of functional human platelets that can be used on demand. Prolytix was chosen as an ideal partner based on their significant scientific expertise and presence in the hemostasis and research communities.
Read the full press release here.